logo

For the Inventor, By the Inventor

Narberth, PA, United States of America

John Scholler

This inventor holds 23 USPTO granted patents and 9 published patent applications and 10 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: University of Pennsylvania, Novartis Ag, University of Pittsburgh. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Scholler. Retrieved from https://idiyas.com/inventor/john-scholler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.5

ph-index = 7

Forward Citations = 349(Granted Patents)


Location History:

  • Penn Valley, PA (US) (2016 - 2023)
  • Narberth, PA (US) (2016 - 2024)

Company Filing History:

goldMedal21 out of 2,655 
 
University of Pennsylvania
 patents
silverMedal7 out of 3,975 
 
Novartis Ag
 patents
bronzeMedal4 out of 1,959 
 
University of Pittsburgh
 patents
4. 3 out of 246 
 
The Wistar Institute
 patents
5. 1 out of 5 
 
Tilt Biotherapeutics Oy
 patents
where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Chimeric Antigen Receptor
Cancer Treatment
T Cell Persistence
Anti-EGFRvIII
ICOS-based CARs
CD2 Signaling Domain
Stromal Cell Targeting
Anti-CD123
Humanized Therapy
Tumor Immunotherapy
23 patents (USPTO):Explore Patents
1. 12653850 - COMBINATION THERAPY USING A CHIMERIC ANTIGEN RECEPTOR (2026-06-16),
2. 12559562 - TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR (2026-02-24),
3. 12350334 - Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer (2025-07-08),
4. 12234274 - Use of the CD2 signaling domain in second-generation chimeric antigen receptors (2025-02-25),
5. 11958892 - Use of ICOS-based cars to enhance antitumor activity and car persistence (2024-04-16),
6. 11865167 - Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor (2024-01-09),
7. 11718685 - Compositions and methods for targeting stromal cells for the treatment of cancer (2023-08-08),
8. 11597754 - Use of the CD2 signaling domain in second-generation chimeric antigen receptors (2023-03-07),
9. 11299536 - Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer (2022-04-12),
10. 11028177 - Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells (2021-06-08),
11. 10927184 - Treatment of cancer using humanized anti-CD19 chimeric antigen receptor (2021-02-23),
12. 10800840 - Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer (2020-10-13),
13. 10577407 - Use of ICOS-based CARS to enhance antitumor activity and CAR persistence (2020-03-03),
14. 10501519 - Use of the CD2 signaling domain in second-generation chimeric antigen receptors (2019-12-10),
15. 10329355 - Compositions and methods for targeting stromal cells for the treatment of cancer (2019-06-25),

Title: Unveiling the Pioneering Work of Inventor John Scholler

Introduction:

John Scholler, a distinguished inventor based in Narberth, PA, has made significant contributions to the field of cancer treatment through his innovative patented technologies.

Latest Patents:

1. "Use of ICOS-based cars to enhance antitumor activity and car persistence": This patent focuses on administering genetically modified Th17 cells to treat cancer by expressing a CAR with specific domains for effective treatment.

2. "Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor": This patent reveals compositions and methods for combating diseases associated with EGFRvIII expression by using chimeric antigen receptors and genetically modified T cells.

Career Highlights:

With an impressive portfolio of 19 patents, John Scholler has been a driving force in advancing cancer treatment methodologies. He has made notable contributions during his tenure at the University of Pennsylvania and Novartis AG.

Collaborations:

John Scholler has collaborated with esteemed colleagues such as Carl H June and Jennifer Brogdon, enhancing the interdisciplinary nature of his research and fostering innovative solutions in the field of oncology.

Conclusion:

Inventor John Scholler's groundbreaking work exemplifies a commitment to revolutionizing cancer treatment through cutting-edge technologies. His patents and collaborations underscore his dedication to improving patient outcomes and advancing the boundaries of medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…